Tilray Brands Inc vs Tesla, Inc. — how do they compare? Tilray Brands Inc trades at $4.21 (market cap $591.60M), while Tesla, Inc. trades at $366.98 (market cap $1.45T). The key difference: Tesla, Inc. is far larger — about 2451× Tilray Brands Inc's market cap, and Tesla, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| TLRY | TSLA | |
|---|---|---|
Market Cap | $591.60M | $1.45T |
Sector | Health | Consumer Cyclical |
52-Week High | $21.00 | $489.88 |
52-Week Low | $3.88 | $298.16 |
Enterprise Value | $758.73M | $1.43T |
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Tesla (TSLA) trades at $368.16, up 3.98% today, amid a bullish technical signal and recent earnings beats despite a Q2 2026 miss. The stock shows elevated valuation multiples with a P/E of 340.89 and P/S of 12.57, while profitability metrics like a 3.67% net income margin reflect competitive pressures. Positive developments include regulatory approval for driver-assistance software in Europe and a potential cheaper EV launch, though cash flow trends indicate heavy investment spending.
The outlook balances innovation potential in autonomy and energy against valuation concerns and execution risks. Near-term catalysts include Q3 2026 earnings, with the consensus price target of $398.38 suggesting modest upside. Key risks are slowing auto demand, high capex, and reliance on future technology adoption to justify current premiums.
Trailing returns across standard periods
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →